Spinelab, a Winterthur, Switzerland-based developer of motion preserving stabilization systems for the spine, has raised CHF4.7m (approximately $4.9m) in Series C financing.
The round, which brought the total amount raised by the company to date to CHF 20m, was led by BioMedInvest and VI Partners.
The company intends to use the capital to initiate commercial activities in Europe and to complete the development of its second core product. Spinelab’s core product is Elaspine™, a pedicle screw based posterior motion preservation system for thoracolumbar spine.
The company is led by President & CEO Thomas Zehnder and Chairman Gerard Moufflet.
FinSMEs
31/05/2012